Healthy Growth across all verticals in FY'22
Strong In-House API Development
BETA
Brugs DRUGS LTD.
65 %
growth
FY 20-21
FY 21-22
BDL has got an allotment of 14 Acres of land on 95
years lease in a special area allocated for API &
intermediates, where there is a single-window
approval from the pollution department.
The company has a plan to expand its API business
along with new formulations in the coming years
Highlights of FY 2021-22
Received WHO-GMP approval
•The company is aggressively working to file its first CEP (Europe) by
October 2022
• Captive expansion- Adding 1 more line by Aug'22 and focusing on
EU GMP.
⚫13 New products developed in FY21-22
BDL is among very few companies to develop
API of Carfilzomib, Cabozantinib, Afatinib,
Pazopanib & Rucaparib
Received DCGI approval of Cabozantinib
DCGI approval is expected for Rucaparib
1View entire presentation